WHAT IS CLAIMED IS:

1. Use of trofinetide for the manufacture of a medicament for treating Rett syndrome in a subject, wherein trofinetide is to be administered in a daily amount of:

a) 4-10.0 g if the subject weighs between 8-11.9 kg;

b) 10.1-14.0 g if the subject weighs between 12.0-20.0 kg;

c) 14.1-18.0 g if the subject weighs between 20.1-35.0 kg;

d) 18.1-22.0 g if the subject weighs between 35.1-50.0 kg; or

e) 22.1-26 g if the subject weighs between 50.1-150 kg.

2. The use of claim 1, wherein the administration of trofinetide results in an $AUC_{0\text{-}12,\ ss}$ of about 755 μg•h/mL to about 1300 μg•h/mL in the subject.

3. The use of claim 1 or claim 2, wherein the administration of trofinetide results in an $AUC_{0\text{-}12,\ ss}$ of at least about 755 μg•h/mL, at least about 780 μg•h/mL, at least about 790 μg•h/mL, at least about 800 μg•h/mL, at least about 820 μg•h/mL, at least about 840 μg•h/mL, at least about 860 μg•h/mL, at least about 880 μg•h/mL, at least about 900 μg•h/mL, at least about 920 μg•h/mL, at least about 940 μg•h/mL, at least about 960 μg•h/mL, at least about 980 μg•h/mL, at least about 1000 μg•h/mL, at least about 1020 μg•h/mL, at least about 1040 μg•h/mL, at least about 1060 μg•h/mL, at least about 1080 μg•h/mL, at least about 1100 μg•h/mL, at least about 1120 μg•h/mL, at least about 1140 μg•h/mL, at least about 1160 μg•h/mL, at least about 1180 μg•h/mL, at least about 1200 μg•h/mL, at least about 1220 μg•h/mL, at least about 1240 μg•h/mL, at least about 1260 μg•h/mL, or at least about 1280 μg•h/mL in the subject.

4. The use of any one of claims 1-3, wherein the administration of trofinetide to the subject results in a $C_{max,\ ss}$ of about 100 to about 200 μg/mL in the subject.

5. The use of any one of claims 1-4, wherein the administration of trofinetide to the subject results in a $C_{max,\ ss}$ of at least about 100 μg/mL, at least about 110 μg/mL, at least about

120 µg/mL, at least about 130 µg/mL, at least about 140 µg/mL, at least about 150 µg/mL, at least about 160 µg/mL, at least about 170 µg/mL, at least about 180 µg/mL, at least about 190 µg/mL, or at least about 200 µg/mL in the subject.

6. The use of any one of claims 1-5, wherein trofinetide is to be administered to the subject in a single dose per day or in multiple doses per day that sum to the daily amount.

7. The use of claim 6, wherein trofinetide is to be administered to the subject in two doses per day that sum to the daily amount.

8. The use of any one of claims 1-7, wherein trofinetide is to be administered as a pharmaceutical composition comprising trofinetide and a pharmaceutically acceptable carrier.

9. The use of claim 8, wherein the pharmaceutically acceptable carrier comprises water and the pharmaceutical composition is a solution.

10. The use of claim 8, wherein the concentration of trofinetide in the solution is about 0.05 g/mL – 0.7 g/mL in the solution or about 0.2 g/mL in the solution.

11. The use of any one of claims 1-10, wherein trofinetide is to be orally administered to the subject.

12. The use of any one of claims 1-11, wherein the subject is human.

13. The use of claim 12, wherein the subject is female.

14. The use of any one of claims 1-13, wherein the subject is about 18 months to about 20 years old.

15. The use of any one of claims 1-14, wherein the subject has a MECP2 mutation.

16. The use of any one of claims 1-15, wherein the Rett syndrome is atypical Rett syndrome or classic/typical Rett syndrome.

17. An orally administered pharmaceutical composition comprising trofinetide, wherein the pharmaceutical composition is an aqueous solution and further wherein (i) the trofinetide is provided in the solution in an amount of 0.05 g/ml to 0.7 g/ml; (ii) the amount of trofinetide is effective for providing an $AUC_{0\text{-}12,\ ss}$ of at least about 755 μg•h/mL in a subject; and/or (iii) the amount of trofinetide is effective for providing a $Cmax,_{\ ss}$ of at least about 100 μg/mL in a subject.

18. The orally administered pharmaceutical composition according to claim 17, wherein trofinetide is provided in the solution in an amount of 0.05 to 0.6 g/ml, 0.1 to 0.4 g/mL, or 0.15 to 0.3 g/mL.

19. The orally administered pharmaceutical composition according to claim 17 or claim 18, wherein the amount of trofinetide is effective for providing an $AUC_{0\text{-}12,\ ss}$ of about 755 μg•h/mL to about 1300 μg•h/mL in the subject and/or a $C_{max,\ ss}$ of about 100 to about 200 μg/mL in the subject.

20. The orally administered pharmaceutical composition according to any one of claims 17-19, further comprising one or more excipients selected from a preservative, sweetener, flavoring agent, and coloring agent.